Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy

Nature Communications

Volumn 7, Issue , 2016, Pages

  Ghasemi, Reza ^a   Lazear, Eric ^b   Wang, Xiaoli ^b   Arefanian, Saeed ^a   Zheleznyak, Alexander ^a   Carreno, Beatriz M ^b   Higashikubo, Ryuji ^a   Gelman, Andrew E ^a,b   Kreisel, Daniel ^a,b   Fremont, Daved H ^b,c,d   Krupnick, Alexander Sasha ^a,b,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c School of Medicine ^*  (United States)

^d Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD69 ANTIGEN; HYBRID PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 2; JANUS KINASE 1; OMCP MUTIL 2 FUSION PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; INTERLEUKIN 2 RECEPTOR ALPHA; KLRK1 PROTEIN, HUMAN; KLRK1 PROTEIN, MOUSE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; PROTEIN BINDING; RECOMBINANT PROTEIN;

CARDIOVASCULAR SYSTEM; CELLS AND CELL COMPONENTS; GENE EXPRESSION; IMMUNE RESPONSE; PROTEIN; TOXICITY; TUMOR; VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; C57BL 6 MOUSE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; COCULTURE; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SPLEEN CELL; STROMA CELL; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; ANIMAL; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NATURAL KILLER CELL; ORTHOPOXVIRUS;

COWPOX VIRUS;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION REGULATION; GENES, MHC CLASS I; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; MALE; MICE; MUTATION; NEOPLASMS, EXPERIMENTAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; ORTHOPOXVIRUS; PROTEIN BINDING; RECOMBINANT PROTEINS;

EID: 84988892445     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12878     Document Type: Article

References (48)

1. Spangler, J. B. et al. Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity 42, 815-825 (2015).
2. French, A. R. et al. DAP12 signaling directly augments proproliferative cytokine stimulation of NK cells during viral infections. J. Immunol. 177, 4981-4990 (2006).
3. Rosenberg, S. A. et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-484 discussion 484-475 (1989).
4. Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451-5458 (2014).
5. Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
6. Sim, G. C. et al. IL-2 therapy promotes suppressive ICOS) Treg expansion in melanoma patients. J. Clin. Invest. 124, 99-110 (2014).
7. Kolitz, J. E. et al. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120, 1010-1017 (2014).
8. Krieg, C., Letourneau, S., Pantaleo, G. & Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl Acad. Sci. USA 107, 11906-11911 (2010)
9. Heaton, K. M., Ju, G. & Grimm, E. A. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res. 53, 2597-2602 (1993).
10. Raulet, D. H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3, 781-790 (2003).
11. Ullrich, E., Koch, J., Cerwenka, A. & Steinle, A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2, e26097 (2013).
12. Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W. & Jung, H. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31, 413-441 (2013).
13. Giuliani, E., Vassena, L., Cerboni, C. & Doria, M. Release of soluble ligands for the activating NKG2D receptor: one more immune evasion strategy evolved by HIV-1? Curr. Drug Targets 17, 54-64 (2015).
14. Campbell, J. A., Trossman, D. S., Yokoyama, W. M. & Carayannopoulos, L. N. Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D. J. Exp. Med. 204, 1311-1317 (2007).
15. Lazear, E., Peterson, L. W., Nelson, C. A. & Fremont, D. H. Crystal structure of the cowpox virus-encoded NKG2D ligand OMCP. J. Virol. 87, 840-850 (2013).
16. Kreisel, D. et al. Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res. 72, 4311-4317 (2012).
17. Voskoboinik, I., Dunstone, M. A., Baran, K., Whisstock, J. C. & Trapani, J. A. Perforin: structure, function, and role in human immunopathology. Immunol. Rev. 235, 35-54 (2010).
18. Dandamudi, U. B. et al. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a cytokine working group (CWG) study. J. Immunother. 36, 490-495 (2013).
19. Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924-1927 (2006).
20. Ho, E. L. et al. Costimulation of multiple NK cell activation receptors by NKG2D. J. Immunol. 169, 3667-3675 (2002).
21. Smyth, M. J. et al. CD4)CD25) T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176, 1582-1587 (2006).
22. Graham, D. B. et al. Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics. J. Immunol. 177, 2349-2355 (2006).
23. Haan, C. et al. Jak1 has a dominant role over Jak3 in signal transduction through gammac-containing cytokine receptors. Chem. Biol. 18, 314-323 (2011).
24. Sutherland, C. L. et al. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J. Immunol. 168, 671-679 (2002).
25. Ho, E. L. et al. Murine Nkg2d and Cd94 are clustered within the natural killer complex and are expressed independently in natural killer cells. Proc. Natl Acad. Sci. USA 95, 6320-6325 (1998).
26. Smith, H. R. et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl Acad. Sci. USA 99, 8826-8831 (2002)
27. Sanderson, S. & Shastri, N. LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol. 6, 369-376 (1994).
28. Tzeng, A., Kwan, B. H., Opel, C. F., Navaratna, T. & Wittrup, K. D. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc. Natl Acad. Sci. USA 112, 3320-3325 (2015).
29. Letourneau, S. et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc. Natl Acad. Sci. USA 107, 2171-2176 (2010).
30. Hemar, A. et al. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J. Cell Biol. 129, 55-64 (1995).
31. Yu, A., Olosz, F., Choi, C. Y. & Malek, T. R. Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common gamma-chain and a lymphoid cell environment. J. Immunol. 165, 2556-2562 (2000).
32. Chang, S. et al. Unique pulmonary antigen presentation may call for an alternative approach toward lung cancer immunotherapy. Oncoimmunology 2, e23563 (2013).
33. Frese-Schaper, M. et al. Influence of natural killer cells and perforinmediated cytolysis on the development of chemically induced lung cancer in A/J mice. Cancer Immunol. Immunother. 63, 571-580 (2014).
34. Plonquet, A. et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 18, 1209-1215 (2007).
35. Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 superkine. Nature 484, 529-533 (2012).
36. Mitra, S. et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 42, 826-838 (2015).
37. Boyman, O. et al. Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance. Transplant. Proc. 44, 1032-1034 (2012).
38. Tomala, J. et al. Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally. ACS Chem. Biol. 8, 871-876 (2013).
39. Gutbrodt, K. L., Casi, G. & Neri, D. Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice. Mol. Cancer Ther. 13, 1772-1776 (2014).
40. Yamane, B. H., Hank, J. A., Albertini, M. R. & Sondel, P. M. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin. Investig. Drugs 18, 991-1000 (2009).
41. OSullivan, T., Dunn, G. P., Lacoursiere, D. Y., Schreiber, R. D. & Bui, J. D. Cancer Immunoediting of the NK Group 2D Ligand H60a. J. Immunol. 187, 3538-3545 (2011).
42. Carmenate, T. et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190, 6230-6238 (2013).
43. Heaton, K. M. et al. Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor. Cell. Immunol. 147, 167-179 (1993).
44. Imai, K., Matsuyama, S., Miyake, S., Suga, K. & Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356, 1795-1799 (2000).
45. Deng, W. et al. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 348, 136-139 (2015)
46. Margolin, K. et al. Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin. Cancer Res. 13, 3312-3319 (2007).
47. Gorelik, E. & Herberman, R. B. Susceptibility of various strains of mice to urethan-induced lung tumors and depressed natural killer cell activity. J. Natl Cancer Inst. 67, 1317-1322 (1981).
48. Hank, J. A. et al. Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. Clin. Cancer Res. 5, 281-289 (1999).